Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

MENLO PARK, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives today announced Clinical Ophthalmology has published data from a subgroup analysis of the OLYMPIA trial, which showed a single treatment with the TearCare System led to superior symptoms relief across the following primary symptoms endpoints (Ocular Surface Disease Index – OSDI, Symptom Assessment in Dry Eye – SANDE, Eye Dryness – ED) compared to a LipiFlow application in patients with more severe forms of DED due to meibomian gland dysfunction (MGD).1

“Since obstruction of the meibomian glands is the underlying cause of MGD or evaporative dry eye, thorough and comprehensive clearance of the obstruction and the restoration of gland health and meibum…

Read more…

Leave a Reply